Boston Scientific (BSX)
(Delayed Data from NYSE)
$73.69 USD
-0.41 (-0.55%)
Updated May 10, 2024 04:00 PM ET
After-Market: $73.68 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
BSX 73.69 -0.41(-0.55%)
Will BSX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BSX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BSX
Neogen (NEOG) Faces Macroeconomic Issues, Fierce Competition
AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates
BSX: What are Zacks experts saying now?
Zacks Private Portfolio Services
PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up
Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up
Inogen (INGN) Q1 Earnings Top Estimates, Revenues Up Y/Y
Other News for BSX
Boston Scientific Welcomes New Director and Updates Governance
Boston Scientific Corp. stock outperforms competitors on strong trading day
Boston Scientific Elects Dr. Cheryl Pegus to Board of Directors
Apple’s $110B buyback is larger than the market caps of 418 S&P 500 stocks
Steve Cohen’s Point72 Asset Management cuts a group of long-short equity portfolio managers